Browse by author
Lookup NU author(s): Emeritus Professor Philip Home
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Aim: To compare the efficacy and safety of premixed insulin aspart (30% free and 70% protamine-bound, BIAsp 30) with human insulin premix (BHI 30) used in a twice-daily injection regimen in people with Type 1 and Type 2 diabetes. Methods: People with Type 1 and Type 2 diabetes (n=294) using twice-daily insulin were randomized to a 12-week open-label comparison of BIAsp 30 and BHI 30. Efficacy was assessed by analysis of variance of 12-week data, adjusted for baseline level. Results: BIAsp 30 was as effective as BHI 30 based on the primary efficacy measure, HbA1c, mean difference -0.01 (90% confidence interval (CI) -0.14; 0.12) %Hb. Meal-time self-measured blood glucose increment averaged over the three main meals was significantly lower in the BIAsp 30 group than in the BHI 30 group (-0.68 (-1.20; -0.16) mmol/l; P<0.02). Significant improvements were observed after breakfast, before lunch, after dinner and at bedtime (P<0.02-0.05), with blood glucose around 1.0 mmol/l lower in the BIAsp 30 group. The number of major hypoglycaemic episodes with BIAsp 30 was half that with BHI 30. However, the overall risk of both minor and major hypoglycaemia did not differ significantly between treatments. Conclusion: Post-prandial glycaemic control was significantly improved, without increasing the risk of hypoglycaemia, and overall control was similar when people with Type 1 and Type 2 diabetes were treated on a twice-daily regimen with immediate premeal injections of BIAsp 30 compared with BHI 30.
Author(s): Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A
Publication type: Article
Publication status: Published
Journal: Diabetic Medicine
Print publication date: 01/05/2002
Online publication date: 16/05/2002
ISSN (print): 0742-3071
ISSN (electronic): 1464-5491
PubMed id: 12027927
Altmetrics provided by Altmetric